Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Retained Earnings: 2022-2025

Historic Retained Earnings for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to -$117.2 million.

  • InMed Pharmaceuticals' Retained Earnings fell 7.40% to -$119.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.0 million, marking a year-over-year decrease of 7.40%. This contributed to the annual value of -$117.2 million for FY2025, which is 7.48% down from last year.
  • As of FY2025, InMed Pharmaceuticals' Retained Earnings stood at -$117.2 million, which was down 7.48% from -$109.1 million recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Retained Earnings registered a high of -$93.5 million during FY2022, and its lowest value of -$117.2 million during FY2025.
  • Over the past 3 years, InMed Pharmaceuticals' median Retained Earnings value was -$109.1 million (recorded in 2024), while the average stood at -$109.2 million.
  • Data for InMed Pharmaceuticals' Retained Earnings shows a maximum YoY declined of 8.50% (in 2023) over the last 5 years.
  • InMed Pharmaceuticals' Retained Earnings (Yearly) stood at -$93.5 million in 2022, then decreased by 8.50% to -$101.4 million in 2023, then decreased by 7.57% to -$109.1 million in 2024, then declined by 7.48% to -$117.2 million in 2025.